| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/25/2005 | CA2123224C Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of t-lymphocytes |
| 01/25/2005 | CA2103383C Quinazoline derivatives |
| 01/25/2005 | CA2068224C Novel potent inducers of terminal differentiation and method of use thereof |
| 01/20/2005 | WO2005005632A2 SMALL INTERFERING RNA SPECIFIC TO SUB-UNITS $G(A), $G(A)' AND $G(B) OF THE KINASE PROTEIN CK2, AND THE APPLICATIONS OF THE SAME |
| 01/20/2005 | WO2005005631A1 Hla-a24 binding cancer antigen peptide derived from ribin |
| 01/20/2005 | WO2005005627A2 Applications of a new class of enzymes: sulfiredoxines. |
| 01/20/2005 | WO2005005473A1 Methods to modulate the activity of the oestrogen receptor |
| 01/20/2005 | WO2005005443A1 Organosilicon compounds and their use |
| 01/20/2005 | WO2005005442A1 Silicon compounds and their use |
| 01/20/2005 | WO2005005431A2 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups |
| 01/20/2005 | WO2005005427A1 PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS |
| 01/20/2005 | WO2005005426A1 Isethionate salt of a selective cdk4 inhibitor |
| 01/20/2005 | WO2005005390A1 Novel enzyme inhibitor |
| 01/20/2005 | WO2005005389A2 Malonamide derivatives |
| 01/20/2005 | WO2005005367A1 Chemically synthesized and highly unsaturated fatty acid of conjugated type |
| 01/20/2005 | WO2005004988A2 Compositions and methods relating to novel compounds and targets thereof |
| 01/20/2005 | WO2005004942A2 Injectable composite for the magnetocytolysis of bone metastatic cells |
| 01/20/2005 | WO2005004926A1 Dendritic cell infiltrativity activating composition and immune activator |
| 01/20/2005 | WO2005004914A1 MEDICINAL COMPOSITION CONTAINING NF-κB DECOY FOR TREATING AND PREVENTING RESPIRATORY DISEASES AND METHOD OF USING THE SAME |
| 01/20/2005 | WO2005004913A1 Pharmaceutical composition containing decoy and method of using the same |
| 01/20/2005 | WO2005004912A1 Method for treating synovial sarcoma |
| 01/20/2005 | WO2005004904A1 Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants) |
| 01/20/2005 | WO2005004903A1 Method for treating oncological diseases |
| 01/20/2005 | WO2005004898A1 Drug promoting ceramide transport, base sequence for producing the drug, method of measuring activity of promoting ceramide release and method of measuring activity of promoting intermembrane ceramide transfer |
| 01/20/2005 | WO2005004892A1 Plant worms mycelium extracat fraction and composition for oral intake |
| 01/20/2005 | WO2005004889A1 Herbal compositions for the treatment and prevention of prostate disorders |
| 01/20/2005 | WO2005004887A1 Pharmaceutical agent against colon carcinoma and other tumor types |
| 01/20/2005 | WO2005004872A1 Cancer combination therapy comprising azd2171 and zd1839 |
| 01/20/2005 | WO2005004871A1 Combination therapy |
| 01/20/2005 | WO2005004870A1 Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| 01/20/2005 | WO2005004864A1 Benzimidazole derivatives as raf kinase inhibitors |
| 01/20/2005 | WO2005004863A1 Benzimidazole carboxamides as raf kinase inhibitors |
| 01/20/2005 | WO2005004808A2 TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS |
| 01/20/2005 | WO2005004639A1 Process for producing liquid formulation containing raw yeast and liquid formulation |
| 01/20/2005 | WO2004096129A3 Inhibitors of akt activity |
| 01/20/2005 | WO2004089992A8 Modified acacia and use thereof |
| 01/20/2005 | WO2004087758A3 Il 13 receptor alpha 2 antibody and methods of use |
| 01/20/2005 | WO2004087713A8 Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| 01/20/2005 | WO2004087207A3 Method for inducing apoptosis and aneuploidy regression in cancer cells |
| 01/20/2005 | WO2004074218A3 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 01/20/2005 | WO2004073601A3 Process for the preparation of hexacyclic camptothecin derivatives |
| 01/20/2005 | WO2004050698A3 Peptide conjugate useful for cell nucleus molecular imaging and tumor therapy |
| 01/20/2005 | WO2004038408A3 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 14 (gpr14) |
| 01/20/2005 | WO2003072114A8 Vascular therapeutics |
| 01/20/2005 | WO2003066881A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/20/2005 | WO2003062392A3 Methods of treating conditions associated with an edg receptor |
| 01/20/2005 | WO2003057155A3 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 01/20/2005 | WO2003035848A9 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer |
| 01/20/2005 | WO2002050289A8 Methods for the production of multimeric proteins, and related compositions |
| 01/20/2005 | US20050015108 Catheter balloon systems and methods |
| 01/20/2005 | US20050014941 Cyanoalkylamino derivatives as protease inhibitors |
| 01/20/2005 | US20050014833 Cyclic compound and ppar agonist |
| 01/20/2005 | US20050014831 Cancer, hypertension, obesity; diseases mediated by alteration of membrane structure and regulation of G-proteins or receptors |
| 01/20/2005 | US20050014825 Preparation and use of solidified oils |
| 01/20/2005 | US20050014817 Fluorothiophene derivatives, process for preparing them and pharmaceutical compositions containing them |
| 01/20/2005 | US20050014814 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia |
| 01/20/2005 | US20050014811 Such as 4-cyclopentylamino-benzenesulfonic acid 2-(3,4-dimethoxy-phenylamino)-1H-benzoimidazol-5-yl ester; cyclin-dependent kinase inhibitors that are aimed to be more active than flavopiridol |
| 01/20/2005 | US20050014806 Substituted isoxazoles and their use as antibiotics |
| 01/20/2005 | US20050014805 Hypotensive agents; antidiabetic agents; cardiovascular disorders; anticholesterol agents; anticancer agents |
| 01/20/2005 | US20050014803 Enzyme inhibitors |
| 01/20/2005 | US20050014801 Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use |
| 01/20/2005 | US20050014800 Vision defects; anticancer agents; antitumor agents |
| 01/20/2005 | US20050014795 Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same |
| 01/20/2005 | US20050014784 Endostatin-like angiogenesis inhibition |
| 01/20/2005 | US20050014778 Variolin derivatives as anti-cancer agents |
| 01/20/2005 | US20050014776 Steroidal compounds for inhibiting steroid sulphatase |
| 01/20/2005 | US20050014775 Anticancer agents |
| 01/20/2005 | US20050014772 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 01/20/2005 | US20050014769 Anticancer agents; controlling apoptosis |
| 01/20/2005 | US20050014761 Antitumor agents; antiancer agents; antiinflammatory agents; autoimmune disease |
| 01/20/2005 | US20050014760 Methods of treating diseases or conditions using dihydropteridinone compounds |
| 01/20/2005 | US20050014755 Tetracyclic compounds as c-Met inhibitors |
| 01/20/2005 | US20050014746 compounds which bind to the interaction-domain (I-domain) of LFA-1, thus interrupting endothelial cell-leukocyte adhesion by blocking the interaction of LFA-1 with ICAM-1, ICAM-3, and other adhesion molecules |
| 01/20/2005 | US20050014726 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
| 01/20/2005 | US20050014721 reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids |
| 01/20/2005 | US20050014718 Tumor specific oligosaccharide sequences and use thereof |
| 01/20/2005 | US20050014705 E.g., dimethylcarbamic acid, 2-oxo-3-benzyl-4-methyl-2H-1-benzopyran; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 01/20/2005 | US20050014700 Cbi analogues of cc-1065 and the duocarmycins |
| 01/20/2005 | US20050014699 Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 01/20/2005 | US20050014688 Inducer of apoptosis |
| 01/20/2005 | US20050014687 Nucleoc acid sequences coding polypeptides; binding to antibodies; diagnosis, therapy of diseases such as cancer |
| 01/20/2005 | US20050014686 Somatostatin analogues |
| 01/20/2005 | US20050014684 Cycloheptatide; solid phase synthesis; anticancer agents |
| 01/20/2005 | US20050014404 Apparatus for a quick release safety connector assembly |
| 01/20/2005 | US20050014232 Novel tetronic acid derivative |
| 01/20/2005 | US20050014222 Phosphatases which activate map kinase pathways |
| 01/20/2005 | US20050014188 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof |
| 01/20/2005 | US20050014149 Assay for inhibitors of translocases |
| 01/20/2005 | US20050013879 Method for extracting antineoplastic components from Bupleurum scorzonerifolium |
| 01/20/2005 | US20050013875 Immunopotentiators in thermotherapy for cancer |
| 01/20/2005 | US20050013852 Rapid release, water permeable self adhesive polymer matrix system; photodynamic therapy and/or diagnosis of skin lesions |
| 01/20/2005 | US20050013827 Novel molecules of the herpesvirus-entry-mediator-related protein family and uses thereof |
| 01/20/2005 | US20050013808 Nitroreductase enzymes |
| 01/20/2005 | US20050013796 Detection and treatment of breast disease |
| 01/20/2005 | DE10329847A1 Pharmazeutischer Wirkstoff gegen Prostatakarzinome A pharmaceutical agent against prostate cancer |
| 01/20/2005 | DE10327719A1 VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone VEGFR-2 and VEGFR-3 inhibitory Anthranylamidpyridone |
| 01/20/2005 | CA2531859A1 Benzimidazole derivatives as raf kinase inhibitors |
| 01/20/2005 | CA2531856A1 Benzimidazole carboxamides as raf kinase inhibitors |
| 01/20/2005 | CA2531759A1 Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors |
| 01/20/2005 | CA2531643A1 Combination therapy |